Compare GYRE & TREE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GYRE | TREE |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | 618 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 575.4M | 541.5M |
| IPO Year | 2004 | 2008 |
| Metric | GYRE | TREE |
|---|---|---|
| Price | $5.99 | $37.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $17.00 | ★ $71.25 |
| AVG Volume (30 Days) | 90.0K | ★ 174.3K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 443.31 |
| EPS | N/A | ★ 1.22 |
| Revenue | $275,000.00 | ★ $1,117,324,000.00 |
| Revenue This Year | $19.88 | $19.03 |
| Revenue Next Year | N/A | $7.07 |
| P/E Ratio | ★ N/A | $30.20 |
| Revenue Growth | N/A | ★ 24.12 |
| 52 Week Low | $5.44 | $32.65 |
| 52 Week High | $9.42 | $77.35 |
| Indicator | GYRE | TREE |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 45.53 |
| Support Level | $5.44 | $34.50 |
| Resistance Level | $8.13 | $40.00 |
| Average True Range (ATR) | 0.31 | 1.48 |
| MACD | 0.06 | 0.22 |
| Stochastic Oscillator | 45.08 | 38.91 |
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.